Global Prostate Cancer Market Industry Trends and Statistics for 2016-21
prostate cancer market has a high demand for novel drugs that concentrate on unmet needs such as improved survival time, less toxicity, better progression free survival, improved effectiveness, and lesser cost.
(EMAILWIRE.COM, December 06, 2017 ) According to the report Global Prostate Cancer Market, published by Market Data Forecast, the global market is projected to reach USD 75.56 billion by 2021, at a CAGR of 9.5% from 2016 to 2021.
In the vast majority of cases, the prostate cancer starts in the gland cells - this is called adenocarcinoma. In this article, prostate cancer refers just to adenocarcinoma.
Get accurate market forecast and analysis on the Global Prostate Cancer market. Request a free sample to stay up-to-date on the main trends affecting this market http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/request-sample
Prostate cancer is mostly a very slow progressing disease. In fact, many men die of old age, without ever knowing they had prostate cancer - it is only when an autopsy is done that doctors know it was there. Several studies have indicated that perhaps about 80% of all men in their eighties had prostate cancer when they died, but nobody knew, not even the doctor.
Experts say that prostate cancer starts with tiny alterations in the shape and size of the prostate gland cells - Prostatic intraepithelial neoplasia (PIN).
Doctors say that nearly 50% of all 50-year-old men have PIN. The cells are still in place - they do not seem to have moved elsewhere - but the changes can be seen under a microscope. Cancer cells would have moved into other parts of the prostate. Doctors describe these prostate gland cell changes as low-grade or high-grade; high grade is abnormal while low-grade is more-or-less normal.
Any patient who was found to have high-grade PIN after a prostate biopsy is at a significantly greater risk of having cancer cells in his prostate. Because of this, doctors will monitor him carefully and possibly carry out another biopsy later on.
Global Prostate Cancer Market: Drivers & Restraints
The factors such as growing number of novel drugs expected to get launched in short-term future and rising old age male population are driving the growth of the market. Altering lifestyle, technological advancements in researching for new techniques to fight prostate cancer, increase in the funding in both public and private sector in the field of drug advancement are some of the key reasons driving the growth of the market. High cost of treatment is restraining the growth of the market.
Get a comprehensive overview of the Global Prostate Cancer market: http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/
Global Prostate Cancer market: Segmentation
By Diagnostic Techniques
Digital Rectal Exam (DRE)
Prostate Specific Antigen Test (PSA)
By Surgery
Radical Prostatectomy
Orchidectomy
Trans Urethral Resection (TUR)
By Radiation Therapy
External Beam Radiation Therapy
Brachytherapy
By Chemotherapy
Docetaxel
Etoposide
Vinblastine
5 Carboplatin
Vinorelbine
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/customize-report
Global Prostate Cancer market: Overview
Prostate cancer has become the second most common type of cancer affecting men (skin cancer is number one), with approximately 240,000 patients diagnosed each year.1 Their prognosis depends on various factors, such as the stage of the cancer and other patient characteristics, including age, race, and overall health. If prostate cancer is diagnosed early, localized therapies such as prostatectomy and radiotherapy can be used, resulting in a virtual 100% five-year survival rate.2 Unfortunately, the risk of metastases increases as the disease progresses; the most common areas of metastases are the adrenal gland, bone, liver, and lung. A poorer prognosis results as the cancer advances, with a five-year survival rate of 37%.
Traditionally, chemotherapy was the mainstay of treatment for metastatic prostate cancer. Docetaxel was the primary agent because it improved overall survival (OS), but its unfavorable toxicity profile has since relegated it to later-line therapy. Since 2010, multiple hormone therapies have been approved and have become favored options for the treatment of metastatic prostate cancer. They fall into different drug categories and have contributed to overall U.S. market sales estimated at $1.6 billion in 2013.
The pipeline is filled with exciting therapies designed with various mechanisms of action. As physicians continue to gain experience with newer therapies, the reception for future drugs should be positive.
Global Prostate Cancer market: Region-wise Outlook
Based on geography the market is analysed under various regions namely, North America, Latin America, Europe, Asia-Pacific and Middle-East & Africa. North America region holds the largest share in the global prostate cancer market. However, Asia-Pacific and Latin America region are estimated to record the highest CAGR during the forecast period.
Key Questions Answered
What is the current and future Prostate Cancer market outlook worldwide? What trends are affecting the Global market?
What is the competitive landscape and market share of major players in the Prostate Cancer space globally?
What are the key, high growth markets that Prostate Cancer manufacturers should expand into? Which market segments are growing the fastest?
What are the unmet needs with the Prostate Cancer currently on the market? How will emerging technologies fulfil these unmet needs?
What is physician perception and market outlook of Prostate Cancer?
What are the challenges and barriers that have hindered widespread adoption of Prostate Cancer?
Global Prostate Cancer market: Key Players
Major companies include Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech etc. The market registered substantial growth in the recent years, due to the various strategies such as opting for agreements and collaborations, adopted by leading market players.
Reasons to buy Global Prostate Cancer market Report:
Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porters Five Forces Analyses
A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Therapeutics Segment:
Neurological Monitoring Devices Market: http://www.marketdataforecast.com/market-reports/global-neurological-monitoring-devices-market-2232/
In-vitro Diagnostics Market: http://www.marketdataforecast.com/market-reports/global-in-vitro-diagnostics-market-146/
Cervical Cancer Diagnostics Market: http://www.marketdataforecast.com/market-reports/global-cervical-cancer-diagnostics-and-therapeutics-market-829/
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options.
For more information, kindly visit, www.marketdataforecast.com
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
In the vast majority of cases, the prostate cancer starts in the gland cells - this is called adenocarcinoma. In this article, prostate cancer refers just to adenocarcinoma.
Get accurate market forecast and analysis on the Global Prostate Cancer market. Request a free sample to stay up-to-date on the main trends affecting this market http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/request-sample
Prostate cancer is mostly a very slow progressing disease. In fact, many men die of old age, without ever knowing they had prostate cancer - it is only when an autopsy is done that doctors know it was there. Several studies have indicated that perhaps about 80% of all men in their eighties had prostate cancer when they died, but nobody knew, not even the doctor.
Experts say that prostate cancer starts with tiny alterations in the shape and size of the prostate gland cells - Prostatic intraepithelial neoplasia (PIN).
Doctors say that nearly 50% of all 50-year-old men have PIN. The cells are still in place - they do not seem to have moved elsewhere - but the changes can be seen under a microscope. Cancer cells would have moved into other parts of the prostate. Doctors describe these prostate gland cell changes as low-grade or high-grade; high grade is abnormal while low-grade is more-or-less normal.
Any patient who was found to have high-grade PIN after a prostate biopsy is at a significantly greater risk of having cancer cells in his prostate. Because of this, doctors will monitor him carefully and possibly carry out another biopsy later on.
Global Prostate Cancer Market: Drivers & Restraints
The factors such as growing number of novel drugs expected to get launched in short-term future and rising old age male population are driving the growth of the market. Altering lifestyle, technological advancements in researching for new techniques to fight prostate cancer, increase in the funding in both public and private sector in the field of drug advancement are some of the key reasons driving the growth of the market. High cost of treatment is restraining the growth of the market.
Get a comprehensive overview of the Global Prostate Cancer market: http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/
Global Prostate Cancer market: Segmentation
By Diagnostic Techniques
Digital Rectal Exam (DRE)
Prostate Specific Antigen Test (PSA)
By Surgery
Radical Prostatectomy
Orchidectomy
Trans Urethral Resection (TUR)
By Radiation Therapy
External Beam Radiation Therapy
Brachytherapy
By Chemotherapy
Docetaxel
Etoposide
Vinblastine
5 Carboplatin
Vinorelbine
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/customize-report
Global Prostate Cancer market: Overview
Prostate cancer has become the second most common type of cancer affecting men (skin cancer is number one), with approximately 240,000 patients diagnosed each year.1 Their prognosis depends on various factors, such as the stage of the cancer and other patient characteristics, including age, race, and overall health. If prostate cancer is diagnosed early, localized therapies such as prostatectomy and radiotherapy can be used, resulting in a virtual 100% five-year survival rate.2 Unfortunately, the risk of metastases increases as the disease progresses; the most common areas of metastases are the adrenal gland, bone, liver, and lung. A poorer prognosis results as the cancer advances, with a five-year survival rate of 37%.
Traditionally, chemotherapy was the mainstay of treatment for metastatic prostate cancer. Docetaxel was the primary agent because it improved overall survival (OS), but its unfavorable toxicity profile has since relegated it to later-line therapy. Since 2010, multiple hormone therapies have been approved and have become favored options for the treatment of metastatic prostate cancer. They fall into different drug categories and have contributed to overall U.S. market sales estimated at $1.6 billion in 2013.
The pipeline is filled with exciting therapies designed with various mechanisms of action. As physicians continue to gain experience with newer therapies, the reception for future drugs should be positive.
Global Prostate Cancer market: Region-wise Outlook
Based on geography the market is analysed under various regions namely, North America, Latin America, Europe, Asia-Pacific and Middle-East & Africa. North America region holds the largest share in the global prostate cancer market. However, Asia-Pacific and Latin America region are estimated to record the highest CAGR during the forecast period.
Key Questions Answered
What is the current and future Prostate Cancer market outlook worldwide? What trends are affecting the Global market?
What is the competitive landscape and market share of major players in the Prostate Cancer space globally?
What are the key, high growth markets that Prostate Cancer manufacturers should expand into? Which market segments are growing the fastest?
What are the unmet needs with the Prostate Cancer currently on the market? How will emerging technologies fulfil these unmet needs?
What is physician perception and market outlook of Prostate Cancer?
What are the challenges and barriers that have hindered widespread adoption of Prostate Cancer?
Global Prostate Cancer market: Key Players
Major companies include Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech etc. The market registered substantial growth in the recent years, due to the various strategies such as opting for agreements and collaborations, adopted by leading market players.
Reasons to buy Global Prostate Cancer market Report:
Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porters Five Forces Analyses
A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Therapeutics Segment:
Neurological Monitoring Devices Market: http://www.marketdataforecast.com/market-reports/global-neurological-monitoring-devices-market-2232/
In-vitro Diagnostics Market: http://www.marketdataforecast.com/market-reports/global-in-vitro-diagnostics-market-146/
Cervical Cancer Diagnostics Market: http://www.marketdataforecast.com/market-reports/global-cervical-cancer-diagnostics-and-therapeutics-market-829/
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options.
For more information, kindly visit, www.marketdataforecast.com
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results